178 Risk-reducing salpingo-oophorectomy in BRCA mutation patients

• Published in: International journal of gynecological cancer Vol. 33; no. Suppl 3; p. A342
• Main Authors: Loizzi, Vera, Arezzo, Francesca, Mongelli, Michele, Kardhashi, Anila, Silvestris, Erica, Cazzolla, Ambrogio, Difonzo, Tommaso, Cerbone, Marco, Battista, Gaia, Quarto, Pietro, Memmola, Massimiliano, Cormio, Gennaro
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group LTD 01.09.2023
• Subjects: Breast cancer; Hysterectomy; Laparoscopy; Mutation; Oophorectomy; Ovarian cancer; Womens health
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2023-ESGO.721

Introduction/BackgroundBRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development. The study evaluated the risk of tumor cancer in women presenting the BRCA mutations.MethodologyRisk-reducing surgery (RRS) was performed in all patients carrying BRCA1 (aged between 30–73 years, median age was 51 years) and BRCA 2 mutation (aged between 36–70 years, median age was 53 years) referred at University of Bari, Italy. Fifty-eight percent of the patient population had previous history of breast cancer.ResultsOne hundred and ninty-one patients underwent risk-reducing surgery (RRS) for their BRCA1/2 mutations. Of them, 82% of the women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 7% underwent laparoscopic RRSO and contextual hysterectomy, 1% underwent RRSO through a laparotomic approach and 10 a laparotomic RRSO and hysterectomy. During laparoscopic RRSO, 5% of the patients underwent a prophylactic bilateral mastectomy. Early and late complication occurred in only 2 women. Five patients (3%) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and seven patients (4%) occult cancer.ConclusionRRSO is safe and feasible in BRCA 1/2 mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.DisclosuresNo discosures